^
Association details:
| Biomarker: | SLC44A4 expression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | ASG 5ME (Microtubule inhibitor, SLC44A4-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
Excerpt:
Human cancer xenograft models were selected for in vivo testing on the basis of having favorable SLC44A4 expression...Antitumor activity of ASG-5ME, nab-paclitaxel, or the combination was evaluated in LAPC-9AI prostate xenograft models...In the LAPC-9AI model (day 13), neither ASG-5ME (0.5 mg/kg) nor nab-paclitaxel (60 mg/kg), both administered every four days for a total of four doses, demonstrated antitumor activity as single agents, while nab-paclitaxel at 120 mg/kg demonstrated significant antitumor activity compared with the control (40.3% TGI, p = 0.0476) (Fig. 6E). However, in combination, ASG-5ME significantly enhanced activity of nab-paclitaxel dosed at 60 mg/kg resulting in 84% tumor growth inhibition (P< 0.0001).
Secondary therapy:
albumin-bound paclitaxel
DOI:
10.1158/1535-7163.MCT-16-0225
Source:
Title:
The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
Excerpt:
Human cancer xenograft models were selected for in vivo testing on the basis of having favorable SLC44A4 expression...Antitumor activity of ASG-5ME, nab-paclitaxel, or the combination was evaluated in LAPC-9AI prostate xenograft models...In the LAPC-9AI model (day 13), neither ASG-5ME (0.5 mg/kg) nor nab-paclitaxel (60 mg/kg), both administered every four days for a total of four doses, demonstrated antitumor activity as single agents, while nab-paclitaxel at 120 mg/kg demonstrated significant antitumor activity compared with the control (40.3% TGI, p = 0.0476) (Fig. 6E). However, in combination, ASG-5ME significantly enhanced activity of nab-paclitaxel dosed at 60 mg/kg resulting in 84% tumor growth inhibition (P< 0.0001).
DOI:
10.1158/1535-7163.MCT-16-0225
